KHTRF News and Press, Knight Therapeutics Inc From 05/04/23

MONTREAL, May 04, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2023 financial results on Thursday, May 11, 2023 prior to market opening. Following the release...

MONTREAL, April 18, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:  GUD) (“Knight”), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update a...

MONTREAL, March 24, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”) is pleased to announce it has been included on The Globe and Mail’s 2023 Report on Business magazine’s Women Lead Here list. This annual editorial...

2023-03-23 12:15:10 ET Knight Therapeutics Inc. (KHTRF) Q4 2022 Earnings Conference Call March 23, 2023 8:30 am ET Company Participants Samira Sakhia - President, Chief Executive Officer Jeff Martens - Global Vice President, Commercial Arvind Utchanah - Chief Fin...

2023-03-23 08:36:05 ET Knight Therapeutics press release ( OTCPK:KHTRF ): Q4 GAAP EPS of -C$0.13. Revenue of C$81.66M (+40.1% Y/Y). For the quarter ended December 31, 2022, gross margin as a percentage of revenues was 45% compared to 48% in the same prior year period. ...

MONTREAL, March 23, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading Pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2022. All currency amoun...

MONTREAL, March 16, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2022 financial results on Thursday, March 23, 2023 prior to market opening. Fol...

Knight Therapeutics Inc. (KHTRF) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Samira Sakhia - President and CEO Jeff Martens - Global VP of Commercial Arvind Utchanah - CFO Amal Khouri - Chief Business Officer Confe...

Knight Therapeutics press release ( OTCPK:KHTRF ): Q3 net income was C$1.59M compared to net loss of C$8.59M for the same period in prior year. Revenue of C$72.28M (-1.4% Y/Y). As at September 30, 2022, Knight had C$145.14M in cash, cash equivalents and marketable securiti...

Summary RIGL hoped to expand the label of its drug Tavalisse (fostamatinib), but the failure of the drug in phase 3 appeared to scupper its chances. RIGL sought guidance to see if a reanalysis of the failed phase 3 study might be well received, but it doesn't appear it was. Th...